Genome Editing Market Size, Share & Trends Report

Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method (Ex-vivo, In-vivo), By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-1-68038-399-7
Number of Pages: 130
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Genome Editing Technology Scope Outlook (Revenue, USD Million, 2018 - 2030)
- (CRISPR)/Cas9
- TALENs/MegaTALs
- ZFN
- Meganucleases
- Others
Genome Editing Delivery Method Scope Outlook (Revenue, USD Million, 2018 - 2030)
- Ex-vivo
- In-vivo
Genome Editing Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
- Genetic Engineering
  - Cell line engineering
  - Animal genetic engineering
  - Plant genetic engineering
  - Others
- Clinical Applications
  - Diagnostics
  - Therapy Development
Genome Editing Mode Scope Outlook (Revenue, USD Million, 2018 - 2030)
- Contract
- In-house
Genome Editing End-use Scope Outlook (Revenue, USD Million, 2018 - 2030)
- Biotechnology and pharmaceutical companies
- Academic and government research institutes
- Contract research organizations
Genome Editing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Genome Editing Market, By Technology
    - Mega-nucleases
    - (CRISPR)/Cas9
    - TALENs/MegaTALs
    - ZFN
    - Others
  - North America Genome Editing Market, By Delivery Method
    - Ex-vivo
    - In-vivo
  - North America Genome Editing Market, By Application
    - Genetic Engineering
      - Cell line engineering
      - Animal genetic engineering
      - Plant genetic engineering
      - Others
    - Clinical Applications
      - Diagnostics
      - Therapy Development
  - North America Genome Editing Market, By mode
    - Contract
    - In-house
  - North America Genome Editing Market, By End-use
    - Biotechnology and pharmaceutical companies
    - Academic and government research institutes
    - Contract research organizations
  - U.S.
    - U.S. Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - U.S. Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - U.S. Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - U.S. Genome Editing Market, By mode
    - U.S. Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Canada
    - Canada Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Canada Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Canada Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Canada Genome Editing Market, By mode
    - Canada Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
- Europe
  - Europe Genome Editing Market, By Technology
    - Mega-nucleases
    - (CRISPR)/Cas9
    - TALENs/MegaTALs
    - ZFN
    - Others
  - Europe Genome Editing Market, By Delivery Method
    - Ex-vivo
    - In-vivo
  - Europe Genome Editing Market, By Application
    - Genetic Engineering
      - Cell line engineering
      - Animal genetic engineering
      - Plant genetic engineering
      - Others
    - Clinical Applications
      - Diagnostics
      - Therapy Development
  - Europe Genome Editing Market, By mode
  - Europe Genome Editing Market, By End-use
    - Biotechnology and pharmaceutical companies
    - Academic and government research institutes
    - Contract research organizations
  - UK
    - UK Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - UK Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - UK Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - UK Genome Editing Market, By mode
    - UK Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Germany
    - Germany Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Germany Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Germany Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Germany Genome Editing Market, By mode
    - Germany Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - France
    - France Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - France Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - France Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - France Genome Editing Market, By mode
    - France Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Italy
    - Italy Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Italy Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Italy Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Italy Genome Editing Market, By mode
    - Italy Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Spain
    - Spain Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Spain Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Spain Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Spain Genome Editing Market, By mode
    - Spain Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Denmark
    - Denmark Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Denmark Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Denmark Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Denmark Genome Editing Market, By mode
    - Denmark Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Sweden
    - Sweden Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Sweden Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Sweden Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Sweden Genome Editing Market, By mode
    - Sweden Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Norway
    - Norway Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Norway Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Norway Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
      - Norway Genome Editing Market, By mode
        
        Contract
        
        In-house
    - Norway Genome Editing Market, By End-use
- Asia Pacific
  - Asia Pacific Genome Editing Market, By Technology
    - Mega-nucleases
    - (CRISPR)/Cas9
    - TALENs/MegaTALs
    - ZFN
    - Others
  - Asia Pacific Genome Editing Market, By Delivery Method
    - Ex-vivo
    - In-vivo
  - Asia Pacific Genome Editing Market, By Application
    - Genetic Engineering
      - Cell line engineering
      - Animal genetic engineering
      - Plant genetic engineering
      - Others
    - Clinical Applications
      - Diagnostics
      - Therapy Development
  - Asia Pacific Genome Editing Market, By mode
  - Asia Pacific Genome Editing Market, By End-use
    - Biotechnology and pharmaceutical companies
    - Academic and government research institutes
    - Contract research organizations
  - Japan
    - Japan Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Japan Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Japan Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Japan Genome Editing Market, By mode
    - Japan Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - China
    - China Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - China Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - China Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - China Genome Editing Market, By mode
    - China Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - India
    - India Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - India Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - India Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - India Genome Editing Market, By mode
    - India Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - South Korea
    - South Korea Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - South Korea Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - South Korea Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - South Korea Genome Editing Market, By mode
    - South Korea Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Australia
    - Australia Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Australia Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Australia Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Australia Genome Editing Market, By mode
    - Australia Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Thailand
    - Thailand Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Thailand Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Thailand Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Thailand Genome Editing Market, By mode
    - Thailand Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
- Latin America
- MEA
  - MEA Genome Editing Market, By Technology
    - Mega-nucleases
    - (CRISPR)/Cas9
    - TALENs/MegaTALs
    - ZFN
    - Others
  - MEA Genome Editing Market, By Delivery Method
    - Ex-vivo
    - In-vivo
  - MEA Genome Editing Market, By Application
    - Genetic Engineering
      - Cell line engineering
      - Animal genetic engineering
      - Plant genetic engineering
      - Others
    - Clinical Applications
      - Diagnostics
      - Therapy Development
  - MEA Genome Editing Market, By mode
  - MEA Genome Editing Market, By End-use
    - Biotechnology and pharmaceutical companies
    - Academic and government research institutes
    - Contract research organizations
  - South Africa
    - South AfricaGenome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - South Africa Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - South Africa Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - South Africa Genome Editing Market, By mode
    - South Africa Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Saudi Arabia
    - Saudi Arabia Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Saudi Arabia Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Saudi Arabia Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Saudi Arabia Genome Editing Market, By mode
    - Saudi Arabia Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - UAE
    - UAE Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - UAE Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - UAE Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - UAE Genome Editing Market, By mode
    - UAE Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations
  - Kuwait
    - Kuwait Genome Editing Market, By Technology
      - Mega-nucleases
      - (CRISPR)/Cas9
      - TALENs/MegaTALs
      - ZFN
      - Others
    - Kuwait Genome Editing Market, By Delivery Method
      - Ex-vivo
      - In-vivo
    - Kuwait Genome Editing Market, By Application
      - Genetic Engineering
        
        Cell line engineering
        
        Animal genetic engineering
        
        Plant genetic engineering
        
        Others
      - Clinical Applications
        
        Diagnostics
        
        Therapy Development
    - Kuwait Genome Editing Market, By mode
    - Kuwait Genome Editing Market, By End-use
      - Biotechnology and pharmaceutical companies
      - Academic and government research institutes
      - Contract research organizations

Genome Editing Market Dynamics

Driver: Success in pre-clinical models driving demand for therapeutics

Recently developed gene editing tools hold enormous potential in human healthcare management. Specifically, the emergence of targeted genome modification that deploys designer nucleases, such as CRISPR and TALEN, has reshaped the investigation of gene function and further development of therapeutics. A broader understanding of genes is achieved using genetically engineered preclinical models. The success of these tools in the development of preclinical models that mimic human physiology and disease genotype & phenotype is expected to enhance the adoption of these technologies. Usage of these preclinical models is expected to grow, as they hold considerable potential to ensure higher success of preclinical research. Biological models developed using gene editing tools are successfully employed to study and treat genetic and rare diseases, including monogenic recessive disorders that affect hematopoietic systems such as Wiskott-Aldrich syndrome and SCID. Hence, with the growth of these preclinical models, this market is expected to witness lucrative expansion.

Driver: Competitive developments in the market

Gene editing technologies continue to gain momentum as an innovative solution for disease diagnostics, treatment, and prevention. As a result of this, genomic research-based companies that have begun to adopt gene editing techniques are observed to multiply in number, while several new market entrants have started embracing the potential of products developed using these technologies. Furthermore, recognition of the significant potential of genetically modified products has fueled the adoption of gene editing technologies. This, in turn, has strengthened the competition amongst firms for capitalizing on the ample avenues present in the marketplace. Understanding the enormous potential of gene editing technology in human and animal disease treatment, this space is witnessing new entries. For instance, CRISPR Therapeutics was founded in April 2014 to work on CRISPR technology. Such developments in the market are expected to foster revenue growth through the forecast period. Rising competition is evident in the presence of an increased number of products that have entered clinical trials or are underway to enter preclinical research. In addition, the market is also expected to benefit from significant mergers & acquisitions, and partnerships between key entities.

Restraint: Challenges regarding clinical translation

DNA editing has been widely adopted for the treatment of highly penetrant disorders and monogenic diseases. Although gene editing holds high potential in disease treatment, its clinical application is surrounded by certain clinical pitfalls, restraining market growth. There is a difference in the rate of activities of HRD and NHEJ which makes disease treatment that requires gene insertion and correction more challenging than those requiring gene inactivation. Despite the significant application of these technologies in disease treatment, their clinical translation poses certain formidable challenges when it comes to application in disease treatment. Major issues with the clinical translation of gene editing involve efficiency in gene correction, improving the specificity of editing nucleases, and its delivery mechanisms. Despite technological advances, CRISPR’s final application to gene therapy still demands enhancements, thereby limiting market growth into clinical therapies.

What Does This Report Include?

This section will provide insights into the contents included in this genome editing market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Genome editing market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Genome editing market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.